N-butyl-N-propyl-acetamide | 115900-21-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-butyl-N-propyl-acetamide
• 英文别名: N-Butyl-N-propyl-acetamid；Acetamide, N-butyl-N-propyl-；N-butyl-N-propylacetamide
• CAS: 115900-21-5
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: XOKMSKQWQKSTDN-UHFFFAOYSA-N

物化性质

• 沸点：
  220.4±8.0 °C(Predicted)
• 密度：
  0.866±0.06 g/cm3(Predicted)
• 保留指数：
  2331

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  亚丁基-丙基-胺 在 乙醇 、 sodium 作用下， 生成 N-butyl-N-propyl-acetamide
  参考文献：
  名称：

  Tiollais, Bulletin de la Societe Chimique de France, 1947, p. 960

  摘要：

  DOI：

文献信息

• 2-Phenyl-2h-pyridazine-3-ones
  申请人：——

  公开号：US20030162662A1

  公开（公告）日：2003-08-28

  The invention relates to 2-phenyl-2H-pyridazin-3-ones of the general formula I 1 in which the variables R 1 , R 2 , X, Y and Z have the following meanings: X is halogen; Y is fluorine or chlorine; Z is oxygen; R 1 is hydrogen or C 1 -C 4 -alkyl; R 2 is chlorine, OR 3 or NR 4 R 5 , in which R 3 , R 4 and R 5 have the meanings indicated in claim 1, Z can also be a group NR 6 if R 2 is a group OR 7 , in which R 6 and R 7 have the meanings indicated in claim 1, and to the agriculturally utilizable salts of compounds of the formula I. The invention furthermore relates to the use of compounds I and their salts as herbicides and/or for the desiccation and/or defoliation of plants, herbicidal compositions and compositions for the desiccation and/or defoliation of plants, which contain the compounds I and/or their salts as active substances, and processes for controlling undesired vegetation (weeds) and for the desiccation and/or defoliation of plants using the compounds I and/or their salts.

  该发明涉及一般式I中的2-苯基-2H-吡啶并三酮，其中变量R1、R2、X、Y和Z具有以下含义：X为卤素；Y为氟或氯；Z为氧；R1为氢或C1-C4-烷基；R2为氯、OR3或NR4R5，其中R3、R4和R5具有权利要求1中所指的含义，如果R2为OR7，则Z也可以是NR6基团，其中R6和R7具有权利要求1中所指的含义，并且该发明还涉及一般式I化合物的农业可利用盐。此外，该发明涉及将化合物I及其盐用作除草剂和/或用于植物脱水和/或落叶，含有化合物I和/或其盐作为活性物质的除草剂组合物和用于植物脱水和/或落叶的组合物，以及利用化合物I和/或其盐控制不受欢迎的植被（杂草）和对植物进行脱水和/或落叶的过程。
• Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
  申请人：——

  公开号：US20030092757A1

  公开（公告）日：2003-05-15

  Disclosed herein is a method for favorably modulating the health-related quality of life and the health-related quality-adjusted time-to-disease progression in a patient having prostate cancer and a method for measuring of the health-related quality-adjusted time-to-disease progression.

  本文揭示了一种有利地调节患有前列腺癌患者的健康相关生活质量和健康相关质量调整的疾病进展时间的方法，以及一种测量健康相关质量调整的疾病进展时间的方法。
• Pyrazolone Derivative
  申请人：Gomi Noriaki

  公开号：US20100324091A1

  公开（公告）日：2010-12-23

  A pyrazolone derivative represented by formula (I) below: wherein R 1 to R 3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

  本发明提供了一种由以下式（I）表示的吡唑酮衍生物：其中，R1至R3与权利要求中定义的相同；或其光学异构体、药学上可接受的盐或其水合物或溶剂化物。根据本发明，这种新型的吡唑酮衍生物具有PAI-1生产抑制活性、组织纤维化抑制活性和纤溶活性，对于预防和/或治疗组织纤维化疾病（肺纤维化、肾脏纤维化等）以及由病理性血栓引起的疾病（缺血性心脏病（心肌梗死和心绞痛）、心房血栓、肺栓塞、深静脉血栓性炎症、弥漫性血管内凝血、缺血性脑疾病（脑梗死、脑出血）和动脉硬化）非常有效。此外，本发明还提供了一种用于预防和/或治疗由纤溶酶原激活剂抑制物-1介导的疾病状况或症状的药物制剂，其包括根据本发明的新型吡唑酮衍生物。
• NEUROGENIC PAIN CONTROL AGENT COMPOSITION
  申请人：Maruishi Pharmaceutical Co., Ltd.

  公开号：EP1749817A1

  公开（公告）日：2007-02-07

  The instant application provides a pharmaceutical composition for controlling neuropathic pain, which comprises a compound of formula: or a salt thereof.

  本申请提供了一种用于控制神经性疼痛的药物组合物，它包括一种式化合物： 或其盐。
• PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP2050749A1

  公开（公告）日：2009-04-22

  A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R1 represents a cyclic substituent].

  本发明提供了一种药物，该药物具有优异的 PI3K 抑制作用以及在体内的稳定性和水溶性，因此可作为癌症的预防或治疗药物。 一种由式 (I) 代表的化合物或其药学上可接受的盐： [其中，X 代表单键等；Y 代表单键等（条件是 X 和 Y 不是同时为单键）；Z 代表氢原子等；m 代表 1 或 2 的整数；R1 代表环状取代基]。